G lycation of proteins is a complex series of parallel and sequential reactions, collectively called the Maillard reaction. It occurs in all tissues and body fluids. Early stage reactions lead to the formation of the early glycation adduct, fructosyl-lysine (FL), and later stage reactions form advanced glycation endproducts (AGEs). FL degrades slowly to form AGEs. Glyoxal, methylglyoxal and 3-deoxyglucosone are also potent glycating agents that are formed by the degradation of glycolytic intermediates, lipid peroxidation and glycated proteins. They react with proteins to form AGEs directly.
Important AGEs quantitatively are the hydroimidazolones derived from arginine residues modified by glyoxal, methylglyoxal and 3-deoxyglucosone -G-H1, MG-H1 and 3DG-H, respectively. Other important and widely studied AGEs, usually found at concentrations approximately 10 times lower than hydroimidazolones, are N ε -carboxymethyl-lysine (CML) and N ε -carboxyethyl-lysine (CEL). Pentosidine is a much studied fluorophoric AGE found at concentrations roughly 100-1,000 times lower than the hydroimidazolones.
FL and AGEs are found at increased concentrations on both extracellular and intracellular proteins in diabetes at sites of development of vascular complications -the retina, renal glomerulus and nerve. 1 Increased intracellular glycation of proteins during hyperglycaemia may induce cell activation, 2 possibly by targeting selected signalling proteins to proteasomal proteolysis. 1 The observation that extracellular proteins modified by AGEs could activate vascular cell dysfunction led to the search for cell surface receptors of AGE-modified proteins. 3 The receptor for advanced glycation endproducts (RAGE) is one such receptor; it has a wellsubstantiated role in vascular cell dysfunction.
RAGE was isolated initially from endothelial cells of bovine lung by Stern, Schmidt and co-workers. 4 The function of RAGE in the lung remains uncertain. RAGE is expressed in human microvascular pericytes and endothelial cells. These cells express splice variants of RAGE:N-terminal truncated, C-terminal truncated and full length forms; only the latter two bind AGE-modified protein. 5 Diabetic mice overexpressing RAGE are susceptible to the development of nephropathy, 6 and diabetic homozygous RAGE null mice are resistant to the development of diabetic nephropathy. 7 These observations confirm a role for RAGE in the development of diabetic nephropathy, and RAGE is probably involved in other vascular complications of diabetes, too. The ligand that activates RAGE in the development of vascular complications is not known: it may be AGE-modified proteins, calgranulins or high mobility group box-1 protein HMGB1 (amphoterin).
AGE-modified proteins are thought to be ligands for RAGE. 4, 5 Many studies of cell activation by RAGE have employed albumin that has been highly modified by AGEs (30-40 modified groups per protein). There is no evidence that such proteins exist in vivo, however. Rather, proteins are modified minimally by AGEs, with only one AGE moiety per protein molecule. 1 Ovalbumin, modified minimally by CML, activated endothelial cells in vitro.
The role of CML as an agonist for RAGE remains enigmatic since the concentration of CML residues in plasma protein of normal healthy human subjects is 10-100 times higher than the dissociation constant of RAGE for AGE-protein ligands, implying that RAGE should be always activated. Also, CML is not the most important AGE quantitatively in vivo. 1, 4 RAGE binding activity of AGE-modified albumin did not correlate with CML content but instead correlated with the high extent of modification by the glycating agent. 8 Moreover, pro-inflammatory responses induced in endothelial cells (attributed to AGE-modified protein agonism of RAGE) were not found when endotoxin-free AGEmodified proteins were prepared. 9 It seems that physiologically there may be more important ligands for RAGE than AGE-modified proteins.
RAGE has been shown to bind members of the S100/calgranulin group of proteins -S100A12 (EN-RAGE) and S100b. 10 S100/calgranulin protein expression was shown to be increased in the kidney of diabetic mice, with and without overexpression of RAGE. 6 S100b induced increased expression of genes linked to inflammatory responses in endothelial cells whereas endotoxin-free AGEmodified protein did not. 9 Currently, cell activation by S100A12 and S100b appears to be a likely important function of RAGE in vivo.
A further ligand for RAGE is HMGB1 protein. HMGB1 is a critical mediator of inflammatory responses in necrosis, sepsis and arthritis. HMGB1 binds RAGE but it also binds toll-like receptors 2 and 4 (TLR2 and TLR4). It binds to macrophages and activates nuclear factor kappa B (NFκB) by TLR2-and TLR4-dependent mechanisms; RAGE plays only a minor role. 11 HMGB1 activates human umbilical endothelial cells and induces expression of adhesion molecules ICAM-1, VCAM-1 and E-selectin, and induces secretion of IL-8 and G-CSF. This activation was 50% inhibited by antibodies directed towards the RAGE. 12 HMGB1 appears to be susceptible to glycation. 13 RAGE was studied initially as a mediator of binding of albumin, highly modified by glycation adducts, to vascular cells. Whether RAGE binds minimally glycated proteins in vivo and activates vascular cells remains unclear. Other lig-EDITORIAL COMMENT
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ands such as S100/calgranulins seem more likely to be linked to RAGE activation in diabetes in vivo. HMGB1 cell signalling may be independent of RAGE but it is conceivable that RAGE may bind HMGB1 when it is damaged by glycation. If RAGE does bind glycated proteins in vivo, the recognition feature may be structurally damaged protein rather than a specific glycation adduct.
